Best Gene Therapy CDMOs in United States

· updated as new inspection, certificate, and trial data enters the platform

Gene Therapy manufacturers on CDMO Signal: 36 listed with manufacturing sites in the United States. 5 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Takeda (also makes its own products, Signal Score 83.4), AGC Biologics (Signal Score 79.9) and Thermo Fisher Scientific (Signal Score 77.6). Outside that set, higher Signal Scores on this list include Pharmaron (Signal Score 86.9), FUJIFILM Diosynth Biotechnologies (Signal Score 86.7) and Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Gene Therapy CDMOs in USA with the most regulatory evidence on file

Catalent
76.1
Tampa, FL
24 FDA inspections · 39 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-22 · VAI
Warning letter 2025-11-20
See the evidence →
FUJIFILM Diosynth Biotechnologies
86.7
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
0 FDA inspections · 35 EMA/MHRA GMP certs
Last FDA inspection: None on file
See the evidence →
AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Thermo Fisher Scientific
77.6
Plainville, MA · Alachua, FL · Cambridge, MA
19 FDA inspections · 10 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-30 · NAI
See the evidence →
Takeda
83.4
Boston, MA · Zurich, CH
4 FDA inspections · 20 EMA/MHRA GMP certs
Last FDA inspection: 2026-04-10 · NAI
See the evidence →
36
CDMOs tracked
34
Fully scored
15
With FDA records
85
FDA inspections
164
EMA/MHRA GMP certs
2
Warning letters

Gene therapy is delivered through viral vectors — AAV, lentiviral, and adenoviral being the three dominant platforms. AAV dominates in vivo systemic delivery (rare disease, ophthalmology, neurology); lentivirus is the workhorse for ex vivo cell engineering including CAR-T; adenoviral vectors remain relevant for vaccines and select gene therapy programs. Most gene therapy CDMOs specialize in one or two vector platforms, and platform experience is the first filter in any sponsor's shortlist.

The ranking below aggregates every CDMO tracked as a gene therapy manufacturer across these platforms. For platform-specific rankings, use the dedicated pages: <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>. For sponsors evaluating end-to-end programs that combine vector manufacturing with downstream cell processing, the <a href="/modality/cell-and-gene-therapy">cell and gene therapy view</a> extends this list with cell therapy CDMOs.

FDA inspection outcomes across these CDMOs: 33 NAI (no action), 50 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (69), Denmark (52), UNITED KINGDOM (36), Germany (18), UNITED STATES (11).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
3
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
4
KB
Durham, NC · Boulder, CO
Hiring · 97+ open roles
84.1 98.5 2 insp · 1 GMP 2026-04-01 · VAI Limited —
5
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
6
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
7
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
8
NW
Vilnius, LT; Waltham (MA), USA
Hiring · 16 open roles
80.8 100.0 0 insp · 8 GMP None on file Available —
9
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
10
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
11
UM
Boston, MA
78.7 96.7 2 insp · 0 GMP 2025-12-18 · VAI — —
12
GZ
Indianapolis, IN · Lexington, MA
Hiring · 26 open roles
78.1 100.0 1 insp · 0 GMP 2025-08-27 · NAI Available —
13
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
14
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
15
AG2
San Carlos, CA
77.6 98.8 1 insp · 0 GMP 2025-04-18 · VAI — —
16
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
17
CI
Cincinnati, OH
Hiring · 2 open roles
Fully evidenced
Academic / national centre
75.1 99.6 2 insp · 0 GMP 2025-02-05 · NAI — 1 program
18
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
19
DH
Washington, DC
Platform provider
73.0 — — None on file — —
20
BB
Durham, NC
In-house manufacturer
70.5 — — None on file — —
21
EM
Baltimore, MD
Also makes its own products
66.1 — — None on file — 4 programs
22
CG
Marlborough, MA · Uppsala, SE
Platform provider
65.5 — — None on file — —
23
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
64.0 — — None on file — —
24
AN
Columbus, OH
63.0 — — None on file Available —
25
AB
Research Triangle, NC · San Sebastian, ES
Also makes its own products
61.8 — — None on file — 10 programs
26
GF
Alameda, CA and South San Francisco
61.5 — — None on file Available —
27
FB
Columbus, OH
Hiring · 15 open roles
61.2 — — None on file Expanding 3 programs
28
MA
College Station, TX
59.0 — — None on file Available —
29
VB
Philadelphia, PA
59.0 — — None on file — —
30
MS
Princeton, NJ
59.0 — — None on file — —
31
WB
59.0 — — None on file — —
32
EB
Waltham, MA
Hiring · 8 open roles
59.0 — — None on file — —
33
VM
Cambridge, MA
59.0 — — None on file — —
34
UB
Shanghai, CN · Boston, MA
Hiring · 1 open role
56.5 — — None on file — —
—
Seal Beach, California, United States
Also makes its own products
Profiled — 3 insp · 0 GMP 2025-10-29 · VAI — —
—
San Diego, California, USA
Profiled — — None on file — —
How we score CDMOs →

What to evaluate in a Gene Therapy CDMO

Vector platform match
The first shortlist filter for any gene therapy program is vector platform. AAV for in vivo systemic; lentiviral for ex vivo cell engineering; adenoviral for vaccines and select high-expression programs. Filter by platform first, then compare within the platform.
Regulatory record on-platform
A CDMO with a strong FDA record on AAV manufacturing doesn't automatically de-risk lentiviral work — inspections are facility- and process-specific. Verify the inspection record on the exact platform and site your program will use.
Capacity match to phase
Early clinical AAV runs at 50-200L; commercial can reach 1000-2000L single-batch. Lentiviral commercial supply is a much narrower field. Confirm the CDMO's capacity headroom at your target phase before shortlisting.
Analytics maturity
Vector analytics — capsid ratio, titer, potency, RCL for lentivirus — drive lot release. A CDMO with qualified, established assays de-risks comparability and tech transfer.

FDA jurisdiction — how the ranking scores US-based CDMOs

The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.

Which US CDMOs also cover EU and UK regulatory geographies?

Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.

How CDMO Signal identifies US manufacturing presence

Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.

Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Gene Therapy CDMOs?
Among Gene Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Takeda, AGC Biologics, Thermo Fisher Scientific. The table above is the full list. CDMOs cannot pay to change a score.
How many Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 15 Gene Therapy CDMOs with FDA inspection records and 164 EMA/MHRA GMP certificates across the group.
What should I look for in a gene therapy CDMO?
Match the vector platform to your program first (AAV / lentiviral / adenoviral). Then verify the CDMO's on-platform inspection record, capacity at your target phase, analytics maturity for that vector type, and a clean FDA and EMA/MHRA record. The individual platform pages have platform-specific detail.
How many gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of AAV, lentiviral, adenoviral, and generally-tagged gene therapy manufacturers. Each is scored independently on the standard four-pillar Signal Score. CDMOs cannot pay to change a score.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Gene Therapy shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Adenoviral Vector CDMOs Cell Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Cell & Gene Therapy Viral Vector